Real-world treatment outcomes before and after chemoimmunotherapy approval in -mutant NSCLC after EGFR-TKI failure: a Japanese cohort study

Kenji M and TY conceived, designed, and coordinated the study. Kenji M, TY, and KT wrote the first draft of the manuscript. Kenji M and TY contributed to the data interpretation. NF, HT, AY, Tomohiro O, MH, TF, YG, AN, SO, YO, Taishi H, Takayo O, Ken M, Koji M, Tae H, SM, RH, KD, and YC critically reviewed the manuscript. TY and KT contributed to the validation and supervision. All the authors have read and approved the final manuscript.

Comments (0)

No login
gif